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Abstract
Phospholemman (PLM), a member of the FXYD family of regulators of ion transport, is
a major sarcolemmal substrate for protein kinases A and C in cardiac and skeletal muscle. In the
heart, PLM co-localizes and co-immunoprecipitates with Na+-K+-ATPase, Na+/Ca2+ exchanger
and L-type Ca2+ channel. Functionally, when phosphorylated at serine68, PLM stimulates Na+K+-ATPase but inhibits Na+/Ca2+ exchanger in cardiac myocytes. In heterologous expression
systems, PLM modulates the gating of cardiac L-type Ca2+ channel. Therefore, PLM occupies a
key modulatory role in intracellular Na+ and Ca2+ homeostasis and is intimately involved in
regulation of excitation-contraction (EC) coupling. Genetic ablation of PLM results in a slight
increase in baseline cardiac contractility and prolongation of action potential duration. When
hearts are subjected to catecholamine stress, PLM minimizes the risks of arrhythmogenesis by
reducing Na+ overload and simultaneously preserves inotropy by inhibiting Na+/Ca2+ exchanger.
In heart failure, both expression and phosphorylation state of PLM are altered and may partly
account for abnormalities in EC coupling. The unique role of PLM in regulation of Na+-K+ATPase, Na+/Ca2+ exchanger and potentially L-type Ca2+ channel in the heart, together with the
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changes in its expression and phosphorylation in heart failure, make PLM a rational and novel
target for development of drugs in our armamentarium against heart failure.

Introduction
Phospholemman (PLM) was initially identified by Larry Jones in 1985 (58) as a 15kDa sarcolemmal (SL) protein that is phosphorylated in response to isoproterenol and is distinct
from phospholamban (PLB)(58). Follow-up studies indicated that this 15-kDa SL protein is also
phosphorylated by protein kinase (PK) C (59) and α-adrenergic agonists (38). In 1991, this 15kDa SL phosphoprotein was purified, the complete protein sequence determined by Edman
degradation, the cDNA cloned, and the name “phospholemman” was coined (53). In 1997, the
human PLM gene is localized to chromosome 19q13.1 (11).
PLM is synthesized as a 92 amino acid peptide containing at its N-terminus a 20 amino
acid signal peptide which is cleaved off during processing. The mature protein contains 72 amino
acid residues with a calculated molecular weight of 8409, but a mobility of ~15 kDa in SDSPAGE gels. The first 17 amino acid residues lie in the extracellular domain. The transmembrane
(TM) region contains 20 amino acids (residues 18-37) while the remaining 35 amino acids
(residues 38-72) at the C-terminus are in the cytoplasm. Palmer et al. (53) also noted sequence
homology between PLM and γ-subunit of Na+-K+-ATPase, as well as a short region of sequence
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similarity between PLM (at its C-terminus facing the cytoplasm) and PLB (at its N-terminus also
facing the cytoplasm). This region of sequence similarity (RSSIRRLST69 in PLM and
RSAIRRAST17 in PLB) contains serines and threonines that are potential phosphorylation sites.
Indeed, serine68 in PLM and serine16 in PLB are phosphorylated by PKA (67, 79).
The extracellular N-terminus of PLM contains a FXYD motif, and the cytoplasmic tail of
dog, human and rat PLM contains 3 serines (at residues 62, 63 and 68) and 1 threonine (at
residue 69) but threonine69 is replaced by serine in mouse PLM. By nuclear magnetic resonance
(NMR) (23) and infrared spectroscopy (2), the TM domain of PLM reconstituted in liposomes is
an α-helix with a maximum tilt of 15-170. Specifically, NMR spectroscopic studies of highly
purified PLM in model micelles indicate that the molecule consists of 4 α-helices: H1 (residues
12-17) is in the extracellular N-terminus, H2 (residues 22-38) is the main TM helix followed by
the short H3 (residues 39-45), and H4 (residues 60-68) in the C-terminus is connected to H3 by a
flexible linker (Fig. 1)(76). In vivo, PKA phosphorylates serine68 while PKC phosphorylates
serine63 and serine68 of PLM (79). In vitro studies using PLM fragments suggest that PKA also
phosphorylates serine63 while PKC phosphorylates threonine69 (25). In adult rat myocytes, ∼46%
of serine68 and ∼16% of serine63 are estimated to be phosphorylated in the resting state (69).
Using phospho-specific anti-PLM antibodies (25, 62), ∼30-40% of PLM in adult rat myocytes
(25, 89) and ∼25% of PLM in guinea pig myocytes (66) are phosphorylated under basal
conditions. In transfected HEK293 cells, ∼30-45 % of exogenous PLM is phosphorylated under
resting conditions (92).
Based on observations on Xenopus oocytes in which PLM is overexpressed, Randall
Moorman suggested that PLM is a hyperpolarization-activated anion-selective channel (46).
When reconstituted in lipid bilayers, PLM forms a channel that is highly selective for taurine
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(12) and is thought to be involved in regulation of cell volume in non-cardiac tissues (15, 47).
The function of PLM in the heart remains unknown until the dawning of the 21st century.
Phospholemman: Founding Member of the FXYD Family of Regulators of Ion Transport
In 2000, Kathy Sweadner described the FXYD family of regulators of ion transport (73),
of which PLM is the first cloned member (FXYD1). At present, there are at least 12 known
FXYD proteins, including γ-subunit of Na+-K+-ATPase (FXYD2), mammary associated tumor 8
kDa (MAT-8 or FXYD3), channel inducing factor (CHIF or FXYD4), dysadherin (FXYD5; also
known as related to ion channel RIC), phosphohippolin (FXYD6), FXYD7, and PLM-S
(FXYD10; the shark homolog of PLM). As a family, FXYD proteins are found predominantly in
tissues involved in solute and fluid transport (kidney, colon, pancreas, mammary gland, liver,
lung, prostate and placenta) or are electrically excitable (heart, skeletal and neural tissues). All
FXYD members have the signature FXYD motif in the N-terminus and a single TM domain.
Except for γ-subunit of Na+-K+-ATPase, all other known members of the FXYD gene family has
at least one serine or threonine within the cytoplasmic tail, indicating potential phosphorylation
sites. PLM is unique among FXYD proteins in that it has consensus sequence for
phosphorylation by PKA (RRXS), PKC (RXXSXR) and never-in-mitosis aspergillus (NIMA)
kinase (FRXS/T). PLM is also a substrate for myotonic dystrophy protein kinase (48). The γsubunit of Na+-K+-ATPase is the only member in the FXYD family boasting two alternative
splice variants (FXYD2a and FXYD2b).
Phospholemman: Regulator of Cardiac Na+-K+-ATPase
In 2002, Kaethi Geering demonstrated that PLM co-immunoprecipitates with α-subunits
of Na+-K+-ATPase in bovine sarcolemma (14). In isolated adult rat cardiac myocytes, PLM colocalizes with α-subunits of Na+-K+-ATPase (Fig. 2). When co-expressed with α- and β-subunits
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of Na+-K+-ATPase in Xenopus oocytes, PLM modulates Na+-K+-ATPase activity primarily by
decreasing Km for Na+ and K+ without affecting Vmax (14). Data obtained from cardiac myocytes
or homogenates indicate that PLM inhibits Na+-K+-ATPase by reducing its apparent affinities for
intracellular Na+ (9, 17) and external K+ (29) or decreasing Vmax (3, 24, 25, 28, 55, 66, 70, 80,
89). When phosphorylated at serine68, PLM relieves its inhibition on Na+-K+-ATPase by
decreasing its apparent Km for Na+ (17, 80) but not for K+ (29) and increasing Vmax (24, 66, 80) .
In terms of molecular interactions between PLM and Na+-K+-ATPase, mutational
analysis suggests that FXYD proteins (FXYD2, 4 and 7) interact with TM9 segment of Na+-K+ATPase (36). Co-immunoprecipitation and covalent cross-linking studies demonstrate the TM
segment of PLM is close to TM2 segment of Na+-K+-ATPase (39). Molecular modeling based
on Ca2+-ATPase crystal structure in the E1ATP-bound conformation suggests that the single TM
segment of FXYD proteins docks into the groove between TM segments 2, 6 and 9 of the αsubunit of Na+-K+-ATPase (39). High resolution crystal structure (2.4 Angstrom) of shark rectal
gland Na+-K+-ATPase in the E2.2K+.Pi state indicates that FXYD proteins interact almost
exclusively with the outside of TM9 of the α-subunit (65). The role of the signature FXYD(Y)
motif is to stabilize interactions between α- and β-subunits of Na+-K+-ATPase and residue D (in
the FXYD motif) caps the helix and defines the membrane border (65). In transfected HEK293
cells, PLM interacts with either α1- or α2-subunit of Na+-K+-ATPase in a 1:1 stoichiometry (9).
Phosphorylation of PLM-S causes it to dissociate from shark Na+-K+-ATPase (42). However,
phosphorylation of PLM did not cause it to dissociate from the α-subunit of Na+-K+-ATPase (9,
66). Despite NMR studies of PLM in micelles showing no major conformational changes on
phosphorylation of serine68 (77), in intact cells examined with fluorescence resonance energy
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transfer (FRET), interaction between PLM and Na+-K+-ATPase is decreased on phosphorylation
of PLM (9, 10).
There are 4 isoforms of the catalytic α-subunits of Na+-K+-ATPase and expression of a
particular α-isoform is both tissue- and species-dependent (7). Human (43, 85) and rabbit (8)
hearts are known to express α1-, α2- and α-3 isoforms while rodent hearts express only α1(ouabain-resistant) and α2-isoforms of Na+-K+-ATPase (4, 66, 72, 80). In both adult rat and
mouse ventricles, the ouabain-sensitive α2-subunit is preferentially localized to the t-tubules (4,
74) and its activity represents <25% of total Na+-K+-ATPase activities (4, 72, 80). PLM coimmunoprecipitates all 3 α-subunits of Na+-K+-ATPase in human and rabbit (8), α1- and α2subunits in mouse (80) and bovine (14), but only α1-subunit in rat (24) and guinea pig (66)
hearts. In both wild-type (WT) mouse (80) and guinea pig (66) ventricular myocytes, PLM
regulates the activity of α1- but not α2-isoform of Na+-K+-ATPase. This conclusion must be
tempered with the recent finding that in “SWAP” mouse (21) in which the ouabain affinities of
the α-subunits are reversed, PLM regulates the apparent affinities for Na+ of both α1- and α2subunitis of Na+-K+-ATPase (9). Together with observations made on Xenopus oocytes
heterologously expressing PLM and Na+-K+-ATPase (6, 14), it is likely the PLM regulates both
α1- and α2-subunits of Na+-K+-ATPase.
Cardiac Excitation-Contraction Coupling
Both α1- (21) and α2-subunits (74) of Na+-K+-ATPase have been implicated in the
control of cardiac contractility. Therefore, modulation of Na+-K+-ATPase activity suggests an
important role for PLM in regulation of inotropy. We will give a brief overview of cardiac
excitation-contraction coupling (Fig. 3) which has previously been reviewed by Don Bers in
detail (5). During the upstroke of the action potential, Na+ enters via Na+ channels and further
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depolarizes the sarcolemma. Depolarization activates the voltage-dependent L-type Ca2+
channels, allowing extracellular Ca2+ to enter as an inward current (ICa), which contributes to the
plateau phase of the action potential. Some Ca2+ also enters via the Na+/Ca2+ exchanger (NCX1)
operating in the reverse mode (3 Na+ out: 1 Ca2+ in) during this phase of the action potential,
although the amount and duration of Ca2+ influx via reverse Na+/Ca2+ exchange vary among
species. Ca2+ entry triggers release of ∼2/3 of Ca2+ stored in the sarcoplasmic reticulum (SR) via
the ryanodine receptor (RyR2). The combination of Ca2+ influx and SR Ca2+ release abruptly
raises the free intracellular Ca2+ concentration ([Ca2+]i), allowing Ca2+ to bind to troponin C and
activate the contractile apparatus. Relaxation requires termination of SR Ca2+ release, and
[Ca2+]i to decline so that Ca2+ can dissociate from troponin C. About 70-92% of myoplasmic
Ca2+ is re-sequestered into the SR by sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA2)
which is under the control of PLB. To maintain steady-state Ca2+ balance, Ca2+ that has entered
during systole is mainly extruded by NCX1 operating in the forward mode (3 Na+ in: 1 Ca2+ out),
with the sarcolemmal Ca2+-ATPase playing a smaller role. Likewise, the small amount of Na+
that has entered during depolarization is extruded by Na+-K+-ATPase during diastole. In this
way, the cardiac myocyte maintains beat-to-beat Ca2+ and Na+ balance. Outward K+ currents
contribute to repolarization phase of the action potential.
Among the many transporters and ion channels involved in cardiac Ca2+ fluxes, NCX1 is
unique in that during an action potential, it participates in Ca2+ influx, [Ca2+]i transient buffering
and Ca2+ efflux (5). The direction of Ca2+ flux (in or out) depends on the thermodynamic driving
force determined by the membrane potential (Em) and the concentrations of Na+ and Ca2+ ions
sensed by NCX1. Other than the determinants of its thermodynamic driving force, remarkably
little is known about the regulation of NCX1.
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In the heart, inhibition of Na+-K+-ATPase by PLM is expected to raise intracellular Na+
concentration ([Na+]i), thereby decreasing the thermodynamic driving force for forward Na+/Ca2+
exchange (Ca2+ efflux) and increasing the driving force for reverse Na+/Ca2+ exchange (Ca2+
influx). Both these actions are expected to increase [Ca2+]i and SR Ca2+ load, thereby enhancing
cardiac contractility. Indeed, inhibition of Na+-K+-ATPase with secondary effects on NCX1 has
long been proposed to be the mechanism of positive inotropy of digitalis glycosides (27).
Phospholemman: First Endogenous Regulator of Cardiac Na+/Ca2+ Exchanger
When PLM is overexpressed (1.4 to 3.5-fold) in adult rat left ventricular (LV) myocytes
by adenovirus-mediated gene transfer (68, 89, 90), expression of SERCA2, α1- and α2-subunits
of Na+-K+-ATPase, NCX1 and calsequestrin remains unchanged. As expected, Na+-K+-ATPase
current (Ipump) is decreased in rat myocytes overexpressing PLM, primarily as a result of decrease
in Vmax rather than changes in apparent Km for Na+ and K+ (89). A totally unexpected finding is
that both contraction and [Ca2+]i transient amplitudes (5.0 mM [Ca2+]o, 1 Hz, 370C) in myocytes
overexpressing PLM are lower, rather than higher, when compared to control rat myocytes
overexpressing green fluorescent protein (GFP)(68). This serendipitous but critical observation
is inconsistent with the theoretical prediction that inhibition of Na+-K+-ATPase by PLM leads to
enhanced cardiac contractility. Because the contractile phenotype of myocytes overexpressing
PLM is similar to that observed in myocytes in which NCX1 is downregulated (75), and opposite
to that in which NCX1 is overexpressed (91), we were the first to propose in 2002 that PLM
directly regulates NCX1 activity, independent of its effects on Na+-K+-ATPase (68). Follow-up
studies in adult rat myocytes demonstrate that PLM co-localizes with NCX1 to the sarcolemma
and t-tubules (90), that PLM co-immunoprecipitates with NCX1 (1, 45), that overexpression of
PLM inhibits Na+/Ca2+ exchange current (INaCa)(69, 90), and that downregulation of PLM by
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antisense increases INaCa (45). Using HEK293 cells that are devoid of NCX1 and PLM, we
demonstrated that cells transfected with NCX1 display the characteristic INaCa, and that cells cotransfected with PLM demonstrate inhibition of INaCa as well as Na+-dependent Ca2+ uptake (1).
In addition, PLM co-immunoprecipitates with NCX1 in transfected HEK293 cells (1), pig
sarcolemmal vesicles (1) and guinea pig ventricular myocyte membranes (82). In cardiac
myocytes isolated from PLM-null mice, INaCa was higher in PLM-null myocytes (87) despite no
differences in NCX1 protein levels (78). The cumulative evidence obtained from 3 model
systems: adult rat myocytes, HEK293 cells and PLM-null mice are all consistent with our
hypothesis that PLM directly regulates NCX1 (13).
NCX1 is a 938 amino acid (939 amino acid in the rat) peptide consisting of an
extracellular N-terminal domain comprising the 1st 5 TM segments, a large intracellular loop
(residues 218-764), and an intracellular C-terminal domain consisting of the last 4 TM segments
(52, 56). The α-repeats of TM segments 2, 3 and 7 of NCX1 are important in ion transport
activity (31, 51) while the large intracellular loop contains the regulatory domains of the
exchanger (35, 37, 40). Using glutathione S-transferase (GST) pulldown assay, we demonstrated
that neither the N- nor the C-terminal TM domains of NCX1 associates with PLM (81). Rather,
the cytoplasmic tail of PLM both physically and functionally interacts with the intracellular loop
(residues 218-358) of NCX1 (81). Using overlapping NCX1 loop deletion mutants, we further
showed that PLM interacts with NCX1 at 2 distinct regions encompassing residues 238-270 and
300-328 (92).
There are significant differences between the mechanisms by which PLM regulates the
activities of NCX1 and Na+-K+-ATPase. First, phosphorylation of PLM at serine68 relieves its
inhibition of Na+-K+-ATPase (17, 24, 66). By contrast, PLM phosphorylated at serine68 is the
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active species that inhibits NCX1 (69, 87). Second, the TM segment of FXYD proteins (and by
inference PLM) interacts with TM segments 2, 6 and 9 of α-subunit of Na+-K+-ATPase (36, 39,
65). By contrast, TM43, a PLM mutant with its cytoplasmic tail truncated, targets correctly to the
sarcolemma (69) but does not co-immunoprecipitate NCX1 (81) and has no effect on myocyte
contractility (69), suggesting little-to-no association between the TM domains of PLM and
NCX1.
Phospholemman: Regulator of Cardiac L-type Calcium Channel
In guinea pig cardiac myocytes, Blaise Peterson recently demonstrated that PLM coimmunoprecipitates not only NCX1 but also L-type Ca2+ channels (Cav1.2)(82). In transfected
HEK293 cells and using Ba2+ as charge carrier, PLM modulates gating kinetics of Cav1.2 but not
Cav2.1 (P/Q-type) or Cav2.2 (N-type) Ca2+ channels (82). Specifically, PLM was found to
modulate 4 important gating processes of Cav1.2 channels: (i) activation kinetics were slowed at
voltages near the threshold for channel activation; (ii) deactivation kinetics were slowed
following voltage steps mimicking human cardiac action potential; (iii) voltage-dependent
inactivation was enhanced at voltages corresponding to the plateau phase of the cardiac action
potential; and (iv) increased number of channels enter a deep inactivated state from which
recovery is slow. When a human cardiac action potential is imposed on HEK293 cells
transfected with Cav1.2 channels, PLM increases Ca2+ influx during the repolarization phase of
the cardiac action potential (82). The role of PLM phosphorylation in the regulation of Cav1.2
gating kinetics remains to be elucidated.
The possibility that in cardiac myocytes, PLM may potentially modulate gating kinetics
of L-type Ca2+ channels, in addition to its known effects on Na+-K+-ATPase and Na+/Ca2+
exchanger, renders the interpretation of the effects of PLM expression/phosphorylation on
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cardiac contractility extremely complex. However, heterologous expression systems often do
not reproduce a protein’s native milieu and may distort the stoichiometry of interaction between
proteins. A good example is the potentiation of ICa by adrenergic agonists, so readily observed in
cardiac myocytes (63, 88), has yet to be reproduced in heterologous expression systems (34). In
addition, using Ca2+ as charge carrier, we did not detect any differences in maximal ICa
amplitude, fast and slow inactivation time constants, slope conductance and test potential at
which maximal ICa occurs between WT and PLM-null myocytes (78). Therefore, the
physiological significance of regulation of Cav1.2 by PLM, while intriguing, remains to be
established in cardiac myocytes.
Regulation of Single Myocyte Contraction by Phospholemman: Na+-K+-ATPase vs. NCX1
In cultured myocytes isolated from PLM-null mice and expressing the phosphomimetic
PLM S68E mutant, INaCa but not Ipump is inhibited (70). This is associated with decreased [Ca2+]i
transient and contraction amplitudes (1 Hz, 370C) measured at 5.0 but not at 1.8 mM [Ca2+]o: the
phenotype that we observed when NCX1 is downregulated (75) or when PLM is overexpressed
(68). By contrast, when cultured PLM-null myocytes overexpress the non-phosphorylable PLM
S68A mutant, Ipump but not INaCa is inhibited (70). This is associated with no changes in [Ca2+]i
transient and contraction amplitudes at both [Ca2+]o. Therefore, under conditions in which
[Ca2+]o is varied to manipulate the thermodynamic driving force for NCX1, regulation of single
cardiac myocyte contractility by PLM is mediated by its inhibitory effects on NCX1 rather than
Na+-K+-ATPase.
When myocytes are subjected to rapid pacing (2 Hz) and isoproterenol (1 µM)
stimulation, [Na+]i initially increases but then starts to decline in WT but not in PLM-null
myocytes (18, 80). [Ca2+]i transient and contraction amplitudes follow the time course of [Na+]i:
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initially increase followed by decline in WT but not PLM-null myocytes. When pacing was
slowed to 0.5 Hz to minimize the steep rise in [Na+]i, both [Ca2+]i transient and contraction
amplitudes increase to a lower steady-state level without any time-dependent decline in both WT
and PLM-null myocytes (80). These observations suggest that under conditions of high [Na+]i,
phosphorylated PLM activates Na+-K+-ATPase to limit intracellular Na+ overload at the expense
of reduced inotropy. Therefore, at the level of a single myocyte, PLM can be shown to regulate
Na+ and Ca2+ fluxes (and hence [Ca2+]i transients and contractility), by either NCX1 or Na+-K+ATPase, depending on experimental manipulations.
Regulation of In Vivo Contractility by Phospholemman: Studies with PLM-null Mice
In 2005, Amy Tucker made a major contribution to the understanding of PLM and
cardiac function by successfully engineering the PLM-null mouse (32). There is mild cardiac
hypertrophy (3, 32, 80), at least partly due to increased fibrosis in PLM-null hearts (80) since
neither LV myocyte length and width (78) nor whole cell membrane capacitance (a measure of
cell surface area)(17, 78) is different between WT and PLM-null myocytes. There are no
differences in protein levels of α1-, α2-, β1- and β2-subunits of Na+-K+-ATPase, SERCA2,
PLB, NCX1 and calsequestrin between wild-type and congenic PLM-null hearts (3, 78). The
majority of proteins that are differentially expressed between WT and PLM-null hearts are
involved in cell metabolism (3). Na+-K+-ATPase enzymatic activity (3), Ipump (17, 70) and INaCa
(70, 87) are higher in PLM-null hearts, as expected from the relief of inhibition of Na+-K+ATPase and NCX1. There are no changes in ICa amplitudes but action potential duration is
prolonged in PLM-null myocytes (78).
The effects of PLM on cardiac contractility in vivo are complicated and controversial.
Using magnetic resonance imaging, Amy Tucker (32) initially reported cardiac hypertrophy and
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increased ejection fraction in PLM-null hearts of mice with mixed genetic background (C57BL/6
and 129/SvJ). By contrast, in vivo hemodynamic measurements made by Mike Shattock with
conductance catheter introduced by LV puncture in open-chest mice demonstrate no significant
differences in measured cardiac indices between WT and PLM-null mice of congenic (C57BL/6)
background (3). Our own data in closed-chest catheterized mice show slightly increased baseline
+dP/dt in congenic PLM-null hearts (80). Different genetic backgrounds, non-invasive imaging
vs. invasive catheterization, different anesthesia, blood loss associated with opening the chest
and LV puncture, and heat dissipation in an open-chest mice, may account for these
discrepancies. The weight of current evidence, however, indicates that PLM-null hearts contract
just as well, if not better, than WT hearts. This is inconsistent with the expectation that with
relief of inhibition of Na+-K+-ATPase, PLM-null hearts should exhibit lower contractility when
compared to WT hearts.
Phospholemman: a Novel Cardiac Stress Protein
When PLM is overexpressed in adult rat LV myocytes, contractility and [Ca2+]i transient
amplitudes measured under physiological conditions (1.8 mM [Ca2+]o, 1 Hz, 370C) are only
slightly less than those measured in control myocytes expressing GFP (68).

Likewise,

contractility and [Ca2+]i transient amplitudes (1.8 mM [Ca2+]o, 1 Hz, 370C) are similar between
WT and PLM-null myocytes (78). Only when the thermodynamic driving force for NCX1 is
altered by varying [Ca2+]o (0.6 or 5.0 mM) are the effects of PLM on myocyte contractility and
[Ca2+]i transients evident (45, 68, 69, 78, 90). The effects of PLM on Na+-K+-ATPase are also
not apparent in myocytes under resting conditions: basal [Na+]i is similar between wild-type and
PLM-null myocytes (17, 80).

Therefore, under resting conditions, PLM is functionally

quiescent.
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In the intact heart, β-adrenergic stimulation increases chronotropy leading to more
frequent depolarizations and increased Na+ entry. In addition, ICa and SERCA2 activity are also
increased in response to β-adrenergic stimulation, resulting in increased Ca2+ entry and SR Ca2+
loading. Elevated SR Ca2+ content available for release largely accounts for the enhanced
inotropy associated with β-adrenergic stimulation. Increased Ca2+ entry must be balanced by
greater Ca2+ efflux mediated by forward NCX1, thereby bringing more Na+ into the myocyte.
This, if unchecked, will lead to cellular Na+ and Ca2+ overload. Don Bers (18) hypothesized that
β-adrenergic agonists increase PLM phosphorylation at serine68, thereby activating Na+-K+ATPase and resulting in lower [Na+]i.

The lower [Na+]i promotes Ca2+ efflux via NCX1,

resulting in lower [Ca2+]i transient and contraction amplitudes (18, 80). Indeed, when hearts in
vivo are stressed with maximal doses of isoproterenol, inotropy (+dP/dt) rises to a peak within 2
minutes followed by decline in WT but not PLM-null hearts (Fig. 4). Therefore, when hearts are
under duress, one of the major functions of PLM is to limit Na+ and Ca2+ overload, thereby
minimizing the risks of arrhythmogenesis apparently at the expense of reduced inotropy.
On the other hand, reduced cardiac contractility under conditions of fight or flight is
clearly not in the best interests of the organism. In 2006 we proposed a coordinated paradigm in
which PLM, upon phosphorylation at serine68, enhances Na+-K+-ATPase activity to minimize
risks of arrhythmogenesis but inhibits Na+/Ca2+ exchanger to preserve inotropy during stress
(87). Our recent experiments provide support for this hypothesis. In PLM-null hearts in which
isoproterenol has little-to-no effects on Na+-K+-ATPase (17, 80), injection of recombinant adenoassociated virus (serotype 9) expressing the phosphomimetic PLM S68E mutant (rAAV9-S68E)
directly into the LV resulted in expression of the mutant protein after 4-5 weeks. PLM S68E
mutant inhibits NCX1 but not Na+-K+-ATPase (70). Isoproterenol stimulation resulted in similar
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increases in [Na+]i but higher +dP/dt in PLM-null hearts expressing PLM S68E mutant when
compared to PLM-null hearts expressing GFP (Fig. 5). Therefore, inhibition of NCX1 by
phosphorylated PLM preserves cardiac contractility under stressful situations.
FXYD Proteins in Aging, Exercise and Disease
PLM expression is 2-fold higher in neonatal rabbit ventricular membranes and declines
within 10 days to the level observed in adults (71). The decrease in PLM expression with
postnatal maturation is concurrent with reduction in Na+-K+-ATPase and Na+/Ca2+ exchanger
(71) and suggests tight coordination of PLM with the 2 ion transporters. With aging, expression
of PLM in sedentary rat skeletal muscle is not altered but the level of α1-subunit of Na+-K+ATPase that co-immunoprecipitates with PLM increases 3-fold (61). There are no detectable
changes of association of α2-subunit of Na+-K+-ATPase with PLM with aging (61).
Acute exercise (treadmill running) in rats increases sarcolemmal PLM in skeletal muscle
by 200-350% due to translocation, but phosphorylation at serine68 appears not the be altered (60).
When senescent rats (26 months-old) are subjected to endurance treadmill running for 13-14
weeks, PLM in skeletal muscle is increased by 150% when compared to sedentary senescent rats
(61). In addition, increased association of PLM with α1-subunit of Na+-K+-ATPase in skeletal
muscle of senescent rats (as compared to young rats) is decreased with endurance treadmill
running (61).
In 2002, using cDNA microarrays containing 86 known genes and 989 unknown cDNAs,
Sehl et al. (64) are the first to report that PLM is 1 of only 19 genes to increase after myocardial
infarction (MI) in the rat. We confirmed that PLM protein levels increased 2.4- and 4-fold at 3
and 7 days post-MI, respectively, in the rat (89). PLM overexpression may very well explain the
depression in both Na+-K+-ATPase (20) and Na+/Ca2+ exchanger (19, 86) activities observed in
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the post-MI rat model. In rat hearts subjected to acute ischemia, PLM is phosphorylated which
leads to profound activation of sarcolemmal Na+-K+-ATPase (24). In isolated perfused mouse
hearts subjected to ischemia/reperfusion, protection against infarction by sildenafil is associated
with increased PLM phosphorylation at serine69 which enhances Na+-K+-ATPase activity during
reperfusion (41). Increased Na+-K+-ATPase activity during acute ischemia ± reperfusion is
critical in maintaining [Na+]i homeostasis in order to minimize the adverse effects of elevated
[Na+]i on contractility and arrhythmogenesis. In human heart failure, protein levels of PLM in
LV homogenates are reduced by 24% (8). In a rabbit model of volume overload heart failure
which is prone to arrhythmias (57), expression of PLM is reduced by 42-48% but
phosphorylation at serine68 is dramatically increased (8). Thus, both altered expression and
phosphorylation of PLM have been observed in various cardiac disease models. In this context, it
is very relevant to note that the 2 classes of drugs that have been clinically proven to be
efficacious in human heart failure, β-adrenergic blockers (lowering PKA activity) and
angiotensin converting enzyme inhibitors (reducing PKC activity), both have PLM as a common
target.
Sepsis is a major clinical problem which is characterized by profound hypotension,
systemic vasodilatation and depression in cardiac contractility. A wide range of inflammatory
cascades is activated during systemic sepsis (54). Increased nitric oxide (NO) by inducible NO
synthase (iNOS) has been suggested to cause depressed cardiac contractility in sepsis (26). In
this light, Helge Rasmussen demonstrated that NO stimulates Na+-K+-ATPase (22, 83) and Mike
Shattock reported (in abstract form) that this is dependent on PLM. Acceleration of Na+-K+ATPase activity by PLM may account for hyperpolarization and relaxation of vascular smooth
muscle (vasodilatation) in addition to depression of cardiac contractility.
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PLM has also been implicated in other diseases. For example, PLM is downregulated in
layer II/III stellate neurons in patients with schizophrenia (30). Rett syndrome, an X-linked
neuro-development disorder that ranks as the second most prevalent cause of mental retardation
in girls (49), is due to heterozygous de novo mutations in the methyl-CpG-binding protein 2
(MeCP2) gene. MeCP2 normally represses PLM transcription through direct interactions with
sequences in the PLM promoter. In patients with Rett syndrome and MeCP2-null mice, PLM is
elevated in neurons in the frontal cortex and cerebellum (16, 33). Increasing neuronal PLM
expression is sufficient to reduce dendritic arborization and spine formation, hallmarks of
neuropathology in patients with Rett syndrome.
Dominant-negative mutation in FXYD2 (γ-subunit of Na+-K+-ATPase) causes defective
routing to the plasma membrane and is the cause of primary renal hypomagnesemia (44).
Increased MAT-8 (FXYD3) expression is associated with tumor progression in human breast,
prostate and colorectal cancers (84). Likewise, dysadherin (FXYD5) expression is altered in a
wide variety of human cancers, including but not limited to breast, gastrointestinal stromal, head
and neck, papillary thyroid, colorectal, non-small cell lung, and testicular cancers, and also
epitheliod sarcoma and malignant melanoma (50).
Future Directions
The physiological role of PLM on regulation of L-type Ca2+ channel needs to be
established in its natural environment. The stoichiometry of interaction between PLM and Na+K+-ATPase, PLM and Na+/Ca2+ exchanger, and PLM and L-type Ca2+ channel, remains to be
determined in cardiac myocytes. The role of PLM in regulating cardiac contractility in vivo,
both in health and disease states, needs further investigation. This will likely require
development of novel genetic models. The effects of oxidative stress and NO on both PLM and
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Na+-K+-ATPase are just beginning to be addressed. For effective but specific drug targeting, the
precise molecular interactions between PLM and Na+-K+-ATPase, and PLM and Na+/Ca2+
exchanger need to be mapped out.
Conclusion
FXYD proteins are emerging not only as novel endogenous regulators of ion transport
but also as important targets in many human diseases including neurological, cardiac and renal
diseases and a wide variety of cancers. Phospholemman (FXYD1) regulates Na+-K+-ATPase,
Na+/Ca2+ exchanger and possibly L-type Ca2+ channel in the heart. Its effects on in vivo cardiac
contractility are complex and remain to be clarified.

When hearts are subjected to stress,

phospholemman minimizes risks of arrhythmogenesis and preserves inotropy. Elucidating the
mechanisms by which alterations or mutations of FXYD proteins are involved in human diseases
will undoubtedly provide novel and rational therapeutic targets.
Acknowledgement
This work was supported in part by National Institutes of Health Grants RO1-HL58672
and RO1-HL74854 (JYC), RO1-HL91096 (JER), and by an American Heart Association
Scientist Development Grant F64702 (TOC).

19

References
1.

Ahlers BA, Zhang XQ, Moorman JR, Rothblum LI, Carl LL, Song J, Wang J,

Geddis LM, Tucker AL, Mounsey JP, and Cheung JY. Identification of an endogenous
inhibitor of the cardiac Na+/Ca2+ exchanger, phospholemman. J Biol Chem 280: 19875-19882,
2005.
2.

Beevers AJ and Kukol A. Secondary structure, orientation, and oligomerization of

phospholemman, a cardiac transmembrane protein. Protein Sci 15: 1127-1132, 2006.
3.

Bell JR, Kennington E, Fuller W, Dighe K, Donoghue P, Clark JE, Jia LG, Tucker

AL, Moorman JR. Marber MS, Eaton P, Dunn MJ and Shattock MJ. Characterisation of the
phospholemman knockout mouse heart: depressed left ventricular function with increased Na/K
ATPase activity. Am J Physiol 294: H613-H621, 2008.
4.

Berry RG, Despa S, Fuller W, Bers DM, and Shattock MJ. Differential distribution

and regulation of mouse cardiac Na+-K+-ATPase alpha1 and alpha2 subunits in T-tubule and
surface sarcolemmal membranes. Cardiovasc Res 73: 92-100, 2007.

20

5.

Bers DM. Cardiac excitation-contraction coupling. Nature 415: 198-205, 2002.

6.

Bibert S, Roy S, Schaer D, Horisberger JD, and Geering K. Phosphorylation of

phospholemman (FXYD1) by protein kinases A and C modulates distinct Na,K-ATPase
isozymes. J Biol Chem 283: 476-486, 2008.
7.

Blanco G and Mercer RW. Isozymes of the Na-K-ATPase: heterogeneity in structure,

diversity in function. Am J Physiol 275: F633-650, 1998.
8.

Bossuyt J, Ai X, Moorman JR, Pogwizd SM, and Bers DM. Expression and

phosphorylation of the Na-pump regulatory subunit phospholemman in heart failure. Circ Res
97: 558-565, 2005.
9.

Bossuyt J, Despa S, Han F, Hou Z, Robia SL, Lingrel JB, and Bers DM. Isoform-

specificity of the Na/K-ATPase association and regulation by phospholemman. J Biol Chem 284:
26749-26757, 2009.
10.

Bossuyt J, Despa S, Martin JL, and Bers DM. Phospholemman phosphorylation alters

its fluorescence resonance energy transfer with the Na/K-ATPase pump. J Biol Chem 281:
32765-32773, 2006.
11.

Chen LS, Lo CF, Numann R, and Cuddy M. Characterization of the human and rat

phospholemman (PLM) cDNAs and localization of the human PLM gene to chromosome
19q13.1. Genomics 41: 435-443, 1997.
12.

Chen Z, Jones LR, O'Brian JJ, Moorman JR, and Cala SE. Structural domains in

phospholemman: a possible role for the carboxyl terminus in channel inactivation. Circ Res 82:
367-374, 1998.

21

13.

Cheung JY, Rothblum LI, Moorman JR, Tucker AL, Song J, Ahlers BA, Carl LL,

Wang J, and Zhang XQ. Regulation of cardiac Na+/Ca2+ exchanger by phospholemman. Ann
NY Acad Sci 1099: 119-134, 2007.
14.

Crambert G, Fuzesi M, Garty H, Karlish S, and Geering K. Phospholemman

(FXYD1) associates with Na,K-ATPase and regulates its transport properties. Proc Natl Acad
Sci U S A 99: 11476-11481, 2002.
15.

Davis CE, Patel MK, Miller JR, John JE, 3rd, Jones LR, Tucker AL, Mounsey JP,

and Moorman JR. Effects of phospholemman expression on swelling-activated ion currents and
volume regulation in embryonic kidney cells. Neurochem Res 29: 177-187, 2004.
16.

Deng V, Matagne V, Banine F, Frerking M, Ohliger P, Budden S, Pevsner J, Dissen

GA, Sherman LS, and Ojeda SR. FXYD1 is an MeCP2 target gene overexpressed in the brains
of Rett syndrome patients and Mecp2-null mice. Human molecular genetics 16: 640-650, 2007.
17.

Despa S, Bossuyt J, Han F, Ginsburg KS, Jia LG, Kutchai H, Tucker AL, and Bers

DM. Phospholemman-phosphorylation mediates the beta-adrenergic effects on Na/K pump
function in cardiac myocytes. Circ Res 97: 252-259, 2005.
18.

Despa S, Tucker AL, and Bers DM. PLM-mediated activation of Na/K-ATPase limits

[Na]i and inotropic state during β-adrenergic stimulation in mouse ventricular myocytes.
Circulation 117: 1849-1855, 2008.
19.

Dixon I, Hata T, and Dhalla N. Sarcolemmal calcium transport in congestive heart

failure due to myocardial infarction in rats. Am J Physiol Heart Circ Physiol 262: H1387-H1394,
1992.

22

20.

Dixon I, Hata T, and Dhalla N. Sarcolemmal Na+-K+-ATPase activity in congestive

heart failure due to myocardial infarction. Am Journal of Physiol Cell Physiol 262: C664-C671,
1992.
21.

Dostanic I, Schultz Jel J, Lorenz JN, and Lingrel JB. The alpha 1 isoform of Na,K-

ATPase regulates cardiac contractility and functionally interacts and co-localizes with the Na/Ca
exchanger in heart. J Biol Chem 279: 54053-54061, 2004.
22.

Figtree GA, Liu CC, Bibert S, Hamilton EJ, Garcia A, White CN, Chia KK,

Cornelius F, Geering K, and Rasmussen HH. Reversible oxidative modification: a key
mechanism of Na+-K+ pump regulation. Circ Res 105: 185-193, 2009.
23.

Franzin CM, Gong XM, Thai K, Yu J, and Marassi FM. NMR of membrane proteins

in micelles and bilayers: the FXYD family proteins. Methods (San Diego, Calif) 41: 398-408,
2007.
24.

Fuller W, Eaton P, Bell JR, and Shattock MJ. Ischemia-induced phosphorylation of

phospholemman directly activates rat cardiac Na/K-ATPase. FASEB J 18: 197-199, 2004.
25.

Fuller W, Howie J, McLatchie L, Weber R, Hastie CJ, Burness K, Pavlovic D, and

Shattock MJ. FXYD1 phosphorylation in vitro and in adult rat cardiac myocytes: threonine 69
is a novel substrate for protein kinase C. Am J Physiol Cell Physiol 296: C1346-C1355, 2009.
26.

Grocott-Mason RM and Shah AM. Cardiac dysfunction in sepsis: new theories and

clinical implications. Intensive Care Medicine 24: 286-295, 1998.
27.

Grupp I, Im W-B, Lee C, Lee S-W, Pecker M, and Schwartz A. Regulation of sodium

pump inhibition to positive inotrophy at low concentrations of ouabain in rat heart muscle. J
Physiol (Lond) 360: 149-160, 1985.

23

28.

Han F, Bossuyt J, Despa S, Tucker AL, and Bers DM. Phospholemman

phosphorylation mediates the protein kinase C-dependent effects on Na+-K+ pump function in
cardiac myocytes. Circ Res 99: 1376-1383, 2006.
29.

Han F, Tucker AL, Lingrel JB, Despa S, and Bers DM. Extracellular potassium

dependence of the Na+-K+-ATPase in cardiac myocytes: isoform specificity and effect of
phospholemman. Am J Physiol Cell Physiol 297: C699-705, 2009.
30.

Hemby SE, Ginsberg SD, Brunk B, Arnold SE, Trojanowski JQ, and Eberwine JH.

Gene expression profile for schizophrenia: discrete neuron transcription patterns in the entorhinal
cortex. Arch Gen Psych 59: 631-640, 2002.
31.

Iwamoto T, Uehara A, Imanaga I, and Shigekawa M. The Na+/Ca2+ exchanger NCX1

has oppositely oriented reentrant loop domains that contain conserved aspartic acids whose
mutation alters its apparent Ca2+ affinity. J Biol Chem 275: 38571-38580, 2000.
32.

Jia LG, Donnet C, Bogaev RC, Blatt RJ, McKinney CE, Day KH, Berr SS, Jones

LR, Moorman JR, Sweadner KJ, and Tucker AL. Hypertrophy, increased ejection fraction,
and reduced Na-K-ATPase activity in phospholemman-deficient mice. Am J Physiol Heart Circ
Physiol 288: H1982-1988, 2005.
33.

Jordan C, Li HH, Kwan HC, and Francke U. Cerebellar gene expression profiles of

mouse models for Rett syndrome reveal novel MeCP2 targets. BMC Medical Genetics 8: 36,
2007.
34.

Lemke T, Welling A, Christel CJ, Blaich A, Bernhard D, Lenhardt P, Hofmann F,

and Moosmang S. Unchanged β-adrenergic stimulation of cardiac L-type calcium channels in
Cav1.2 phosphorylation site S1928A mutant mice. J Biol Chem 283: 34738-34744, 2008.

24

35.

Levitsky DO, Nicoll DA, and Philipson KD. Identification of the high affinity Ca2+-

binding domain of the cardiac Na+/Ca2+ exchanger. J Biol Chem 269: 22847-22852, 1994.
36.

Li C, Grosdidier A, Crambert G, Horisberger JD, Michielin O, and Geering K.

Structural and functional interaction sites between Na,K-ATPase and FXYD proteins. J Biol
Chem 279: 38895-38902, 2004.
37.

Li Z, Nicoll DA, Collins A, Hilgemann D, Filoteo A, Penniston J, Weiss J, Tomich J,

and Philipson KD. Identification of a peptide inhibitor of the cardiac sarcolemmal Na+-Ca2+
exchanger. J Biol Chem 266: 1014-1020, 1991.
38.

Lindemann JP. α-adrenergic stimulation of sarcolemmal protein phosphorylation and

slow responses in intact myocardium. J Biol Chem 261: 4860-4867, 1986.
39.

Lindzen M, Gottschalk KE, Fuzesi M, Garty H, and Karlish SJ. Structural

interactions between FXYD proteins and Na+-K+-ATPase: α/β/FXYD subunit stoichiometry and
cross-linking. J Biol Chem 281: 5947-5955, 2006.
40.

Maack C, Ganesan A, Sidor A, and O'Rourke B. Cardiac sodium-calcium exchanger

is regulated by allosteric calcium and exchanger inhibitory peptide at distinct sites. Circ Res 96:
91-99, 2005.
41.

Madhani M, Hall AR, Cuello F, Charles RL, Burgoyne JR, Fuller W, Hobbs AJ,

Shattock MJ, and Eaton P. Phospholemman Ser-69 phosphorylation contributes to sildenafilinduced cardioprotection against reperfusion injury. Am J Physiol Heart Circ Physiol, in press
2010.
42.

Mahmmoud YA, Vorum H, and Cornelius F. Purification of a phospholemman-like

protein from shark rectal glands. J Biol Chem 275: 35969-35977, 2000.

25

43.

McDonough A, Zhang Y, Shin V, and Frank JS. Subcellular distribution of sodium

pump isoform subunits in mammalian cardiac myocytes. Am J Physiol Cell Physiol 270: C1221C1227, 1996.
44.

Meij IC, Koenderink JB, van Bokhoven H, Assink KF, Groenestege WT, de Pont JJ,

Bindels RJ, Monnens LA, van den Heuvel LP, and Knoers NV. Dominant isolated renal
magnesium loss is caused by misrouting of the Na+-K+-ATPase γ-subunit. Nature Genetics 26:
265-266, 2000.
45.

Mirza MA, Zhang XQ, Ahlers BA, Qureshi A, Carl LL, Song J, Tucker AL,

Mounsey JP, Moorman JR, Rothblum LI, Zhang TS, and Cheung JY. Effects of
phospholemman downregulation on contractility and [Ca2+]i transients in adult rat cardiac
myocytes. Am J Physiol Heart Circ Physiol 286: H1322-1330, 2004.
46.

Moorman JR, Ackerman SJ, Kowdley GC, Griffin M, Mounsey JP, Chen Z, Cala

SE, O'Brian JJ, Szabo G, and Jones LR. Unitary anion currents through phospholemman
channel molecules. Nature 377: 737-740, 1995.
47.

Morales-Mulia M, Pasantes-Morales H, and Moran J. Volume sensitive efflux of

taurine in HEK 293 cells overexpressing phospholemman. Biochem Biophys Acta 1496: 252260, 2000.
48.

Mounsey JP, John III J, Helmke S, Bush E, Gilbert J, Roses A, Perryman M, Jones

LR, and Moorman JR. Phospholemman is a substrate for myotonic dystrophy protein kinase. J
Biol Chem 275: 23362-23367, 2000.
49.

Naidu S. Rett syndrome: a disorder affecting early brain growth. Ann Neurol 42: 3-10,

1997.

26

50.

Nam JS, Hirohashi S, and Wakefield LM. Dysadherin: a new player in cancer

progression. Cancer Letters 255: 161-169, 2007.
51.

Nicoll DA, Hryshko LV, Matsuoka S, Frank JS, and Philipson KD. Mutation of

amino acid residues in the putative transmembrane segments of the cardiac sarcolemmal
Na+/Ca2+ exchanger. J Biol Chem 271: 13385-13391, 1996.
52.

Nicoll DA, Ottolia M, Lu L, Lu Y, and Philipson KD. A new topological model of the

cardiac sarcolemmal Na+/Ca2+ exchanger. J Biol Chem 274: 910-917, 1999.
53.

Palmer CJ, Scott BT, and Jones LR. Purification and complete sequence determination

of the major plasma membrane substrate for cAMP-dependent protein kinase and protein kinase
C in myocardium. J Biol Chem 266: 11126-11130, 1991.
54.

Parrillo JE. Pathogenetic mechanisms of septic shock. New Eng J Med 328: 1471-1477,

1993.
55.

Pavlovic D, Fuller W, and Shattock MJ. The intracellular region of FXYD1 is

sufficient to regulate cardiac Na/K ATPase. FASEB J 21: 1539-1546, 2007.
56.

Philipson KD and Nicoll DA. Sodium-calcium exchange: a molecular perspective. Annu

Rev Physiol 62: 111-133, 2000.
57.

Pogwizd SM, Schlotthauer K, Li L, Yuan W, and Bers DM. Arrhythmogenesis and

contractile dysfunction in heart failure: Roles of sodium-calcium exchange, inward rectifier
potassium current, and residual β-adrenergic responsiveness. Circ Res 88: 1159-1167, 2001.
58.

Presti CF, Jones LR, and Lindemann JP. Isoproterenol-induced phosphorylation of a

15-kilodalton sarcolemmal protein in intact myocardium. J Biol Chem 260: 3860-3867, 1985.

27

59.

Presti CF, Scott BT, and Jones LR. Identification of an endogenous protein kinase C

activity and its intrinsic 15-kilodalton substrate in purified canine cardiac sarcolemmal vesicles.
J Biol Chem 260: 13879-13889, 1985.
60.

Rasmussen MK, Kristensen M, and Juel C. Exercise-induced regulation of

phospholemman (FXYD1) in rat skeletal muscle: implications for Na+-K+-ATPase activity. Acta
Physiol (Oxford, England) 194: 67-79, 2008.
61.

Reis J, Zhang L, Cala S, Jew KN, Mace LC, Chung L, Moore RL, and Ng YC.

Expression of phospholemman and its association with Na+-K+-ATPase in skeletal muscle:
effects of aging and exercise training. J Appl Physiol 99: 1508-1515, 2005.
62.

Rembold CM, Ripley ML, Meeks MK, Geddis LM, Kutchai HC, Marassi FM,

Cheung JY, and Moorman JR. Serine68 phospholemman phosphorylation during forskolininduced swine carotid artery relaxation. J Vasc Res 42: 483-491, 2005.
63.

Reuter H. The dependence of slow inward current in Purkinje fibres on the extracellular

calcium-concentration. J Physiol 192: 479-492, 1967.
64.

Sehl PD, Tai JT, Hillan KJ, Brown LA, Goddard A, Yang R, Jin H, and Lowe DG.

Application of cDNA microarrays in determining molecular phenotype in cardiac growth,
development, and response to injury. Circulation 101: 1990-1999, 2000.
65.

Shinoda T, Ogawa H, Cornelius F, and Toyoshima C. Crystal structure of the sodium-

potassium pump at 2.4 A resolution. Nature 459: 446-450, 2009.
66.

Silverman BZ, Fuller W, Eaton P, Deng J, Moorman JR, Cheung JY, James AF,

and Shattock MJ. Serine68 phosphorylation of phospholemman: acute isoform-specific
activation of cardiac Na/K ATPase. Cardiovasc Res 65: 93-103, 2005.

28

67.

Simmerman HK and Jones LR. Phospholamban: protein structure, mechanism of

action, and role in cardiac function. Physiol Rev 78: 921-947, 1998.
68.

Song J, Zhang XQ, Carl LL, Qureshi A, Rothblum LI, and Cheung JY.

Overexpression of phospholemman alter contractility and [Ca2+]i transients in adult rat myocytes.
Am Journal of Physiol Heart Circ Physiol 283: H576-H583, 2002.
69.

Song J, Zhang XQ, Ahlers BA, Carl LL, Wang J, Rothblum LI, Stahl RC, Mounsey

JP, Tucker AL, Moorman JR, and Cheung JY. Serine 68 of phospholemman is critical in
modulation of contractility, [Ca2+]i transients, and Na+/Ca2+ exchange in adult rat cardiac
myocytes. Am J Physiol Heart Circ Physiol 288: H2342-2354, 2005.
70.

Song J, Zhang XQ, Wang J, Cheskis E, Chan TO, Feldman AM, Tucker AL, and

Cheung JY. Regulation of cardiac myocyte contractility by phospholemman: Na+/Ca2+
exchanger vs. Na+-K+-ATPase. Am J Physiol Heart Circ Physiol 295: H1615-H1625, 2008.
71.

Srivastava S, Cala SE, Coetzee WA, and Artman M. Phospholemman expression is

high in the newborn rabbit heart and declines with postnatal maturation. Biochem Biophys Res
Comm 355: 338-341, 2007.
72.

Sweadner KJ, Herrera V, Amato S, Moellmann A, Gibbons D, and Repke K.

Immunologic identification of Na+, K+-ATPase isoforms in myocardium. Circ Res 74: 669-678,
1994.
73.

Sweadner KJ and Rael E. The FXYD gene family of small ion transport regulators or

channels: cDNA sequence, protein signature sequence, and expression. Genomics 68: 41-56,
2000.

29

74.

Swift F, Tovsrud N, Enger UH, Sjaastad I, and Sejersted OM. The Na+-K+-ATPase

α2-isoform regulates cardiac contractility in rat cardiomyocytes. Cardiovasc Res 75: 109-117,
2007.
75.

Tadros GM, Zhang XQ, Song J, Carl LL, Rothblum LI, Tian Q, Dunn J, Lytton J,

and Cheung JY. Effects of Na+/Ca2+ exchanger downregulation on contractility and [Ca2+]i
transients in adult rat myocytes. Am J Physiol Heart Circ Physiol 283: H1616-1626, 2002.
76.

Teriete P, Franzin CM, Choi J, and Marassi FM. Structure of the Na,K-ATPase

regulatory protein FXYD1 in micelles. Biochemistry 46: 6774-6783, 2007.
77.

Teriete P, Thai K, Choi J, and Marassi FM. Effects of PKA phosphorylation on the

conformation of the Na,K-ATPase regulatory protein FXYD1. Biochim Biophys Acta
1788:2462-2470, 2009.
78.

Tucker AL, Song J, Zhang XQ, Wang J, Ahlers BA, Carl LL, Mounsey JP,

Moorman JR, Rothblum LI, and Cheung JY. Altered contractility and [Ca2+]i homeostasis in
phospholemman-deficient murine myocytes: Role of Na+/Ca2+ exchange. Am J Physiol Heart
Circ Physiol 291: H2199-H2209, 2006.
79.

Waalas SI, Czernik AJ, Olstad OK, Sletten K, and Walaas O. Protein kinase C and

cyclic AMP-dependent protein kinase phosphorylate phospholemman, an insulin and adrenalineregulated membrane phosphoprotein, at specific sites in the carboxy terminal domain. Biochem J
304: 635-640, 1994.
80.

Wang J, Gao E, Song J, Zhang XQ, Li J, Koch WJ, Tucker AL, Philipson KD, Chan

TO, Feldman AM, and Cheung JY. Phospholemman and β-adrenergic stimulation in the heart.
Am J Physiol Heart Circ Physiol 298: H807-H815, 2010.

30

81.

Wang J, Zhang XQ, Ahlers BA, Carl LL, Song J, Rothblum LI, Stahl RC, Carey

DJ, and Cheung JY. Cytoplasmic tail of phospholemman interacts with the intracellular loop of
the cardiac Na+/Ca2+ exchanger. J Biol Chem 281: 32004-32014, 2006.
82.

Wang X, Gao G, Guo K, Yarotskyy V, Huang C, Elmslie KS, and Peterson BZ.

Phospholemman modulates the gating of cardiac L-type calcium channels. Biophys J 98: 11491159, 2010.
83.

William M, Vien J, Hamilton E, Garcia A, Bundgaard H, Clarke RJ, and

Rasmussen HH. The nitric oxide donor sodium nitroprusside stimulates the Na+-K+ pump in
isolated rabbit cardiac myocytes. J Physiol 565: 815-825, 2005.
84.

Yamamoto H, Okumura K, Toshima S, Mukaisho K, Sugihara H, Hattori T, Kato

M, and Asano S. FXYD3 protein involved in tumor cell proliferation is overproduced in human
breast cancer tissues. Biological Pharmaceutical Bull 32: 1148-1154, 2009.
85.

Zahler R, Gilmore-Hebert M, Baldwin JC, Franco K, and Benz EJ, Jr. Expression of

alpha isoforms of the Na,K-ATPase in human heart. Biochim Biophys Acta 1149: 189-194, 1993.
86.

Zhang XQ, Tillotson DL, Moore RL, Zelis R, and Cheung JY. Na+/Ca2+ exchange

currents and SR Ca2+ contents in postinfarction myocytes. Am Journal of Physiol 271: C1800C1807, 1996.
87.

Zhang XQ, Ahlers BA, Tucker AL, Song J, Wang J, Moorman JR, Mounsey JP,

Carl LL, Rothblum LI, and Cheung JY. Phospholemman inhibition of the cardiac Na+/Ca2+
exchanger. Role of phosphorylation. J Biol Chem 281: 7784-7792, 2006.
88.

Zhang XQ, Moore RL, Tillotson DL, and Cheung JY. Calcium currents in

postinfarction rat cardiac myocytes. Am J Physiol 269: C1464-1473, 1995.

31

89.

Zhang XQ, Moorman JR, Ahlers BA, Carl LL, Lake DE, Song J, Mounsey JP,

Tucker AL, Chan YM, Rothblum LI, Stahl RC, Carey DJ, and Cheung JY. Phospholemman
overexpression inhibits Na+-K+-ATPase in adult rat cardiac myocytes: Relevance to decreased
Na+ pump activity in post-infarction myocytes. J Appl Physiol 100: 212-220, 2006.
90.

Zhang XQ, Qureshi A, Song J, Carl LL, Tian Q, Stahl RC, Carey DJ, Rothblum LI,

and Cheung JY. Phospholemman modulates Na+/Ca2+ exchange in adult rat cardiac myocytes.
Am J Physiol Heart Circ Physiol 284: H225-233, 2003.
91.

Zhang XQ, Song J, Rothblum LI, Lun M, Wang X, Ding F, Dunn J, Lytton J,

McDermott PJ, and Cheung JY. Overexpression of Na+/Ca2+ exchanger alters contractility and
SR Ca2+ content in adult rat myocytes. Am J Physiol Heart Circ Physiol 281: H2079-2088, 2001.
92.

Zhang XQ, Wang J, Carl LL, Song J, Ahlers BA, and Cheung JY. Phospholemman

regulates cardiac Na+/Ca2+ exchanger by interacting with the exchanger's proximal linker
domain. Am J Physiol Cell Physiol 296: C911-921, 2009.

Figure Legends.
Figure 1. Molecular model of phospholemman. Nuclear magnetic resonance studies of highly
purified phospholemman in micelles revealed 4 helices of the protein with a single
transmembrane domain (after Francesca Marassi)(23, 76). The FXYD motif is in the
extracellular domain and the important serine63 and serine68 are in the cytoplasm.
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Figure 2. Phospholemman co-localizes with α1-subunit of Na+-K+-ATPase. Indirect
immunofluorescence of adult rat ventricular myocytes doubly labeled with mouse monoclonal
antibody against α1-subunit of Na+-K+-ATPase (A) and rabbit polyclonal anti-PLM antibody (B)
are shown. Primary antibodies are visualized with Alexa Fluor 488-labeled goat anti-mouse IgG
(A) and Alexa Fluor 594- labeled goat anti-rabbit IgG (B). Note the orange color in the merged
image (C), indicating co-localization of PLM and Na+-K+-ATPase. Bar = 5 µm.
Figure 3. Cardiac excitation-contraction coupling. Membrane depolarization is initiated by opening
of the Na+ channel (not shown) with Na+ entry. Extracellular Ca2+ enters via L-type Ca2+ channel (ICa)
and Na+/Ca2+ exchanger (NCX1), causing Ca2+ release from the ryanodine receptor (RyR) in the
sarcoplasmic reticulum (SR). Ca2+ binds to troponin and initiates myofilament contraction. During
diastole, Ca2+ is pumped back to the SR by SR Ca2+-ATPase (SERCA) under the control of
phospholamban (PLB). A small amount of Ca2+ is also taken up by the mitochondrial Ca2+ uniporter.
The amount of Ca2+ that has entered during systole is extruded by Na+/Ca2+ exchanger and to a lesser
extent, by sarcolemmal Ca2+-ATPase. Na+ that has entered via Na+ channel and Na+/Ca2+ exchanger is
pumped out by Na+-K+-ATPase. Repolarization is mediated by opening of K+ channels (only the
transient outward K+ current Ito responsible for early repolarization is shown). Phospholemman (PLM)
associates with and is an endogenous regulator of Na+/Ca2+ exchanger, Na+-K+-ATPase and possibly Ltype Ca2+ channel. Na+/Ca2+ exchanger is depicted as operating in the forward mode (Ca2+ efflux) in the
sarcolemma and reverse mode (Ca2+ influx) in the t-tubules. Broken arrows point to ion transporters,
ion channels and myofilaments that are altered after myocardial infarction.
Figure 4. Effects of activation of Na+-K+-ATPase by phosphorylated phospholemman on βadrenergic response in vivo. Shown are normalized in vivo hemodynamics (+dP/dt) of anesthetized
wild-type (•; n=9) and phospholemman-null (; n=14) mice after stimulation with 25 ng of
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isoproterenol. Note time-dependent decline of +dP/dt in wild-type but not phospholemman-null hearts.
Phospholemman phosphorylated at serine68 activates Na+-K+-ATPase (17, 80), leading to decreases in
[Na+]i in wild-type but not phospholemman-null cardiac myocytes (18, 80).
Figure 5. Effects of inhibition of Na+/Ca2+ exchanger by phosphorylated phospholemman on βadrenergic response in vivo. Left ventricles of phospholemman-null (KO) mice are injected with
recombinant adeno-associated virus, serotype 9, expressing either green fluorescent protein (GFP)(;
n=5) or the phosphomimetic phospholemman S68E mutant (•; n=7). S68E mutant inhibits Na+/Ca2+
exchanger but has no effect on Na+-K+-ATPase (69, 70, 87). Five weeks after virus injection, in vivo
hemodynamics (+dP/dt) are measured in anesthetized mice (80). Note with increasing doses of
isoproterenol, KO-S68E hearts contract significantly better than KO-GFP hearts. Since isoproterenol
has no effect on Na+-K+-ATPase in phospholemman-null myocytes (17, 80), [Na+]i is similar between
KO-S68E and KO-GFP hearts (data not shown). Enhanced contractility in KO-S68E hearts is therefore
due to inhibition of Na+/Ca2+ exchanger by the S68E mutant.
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